Skip Navigation LinksHome > Professional Development > eLearning > TACO and Beyond

TACO and Beyond

Please note: AABB reserves the right to make updates to this program.

Tuesday, September 18, 2018
2:00 – 3:00 PM (ET) 7:00 – 8:00 PM (GMT)
Master Program Number: 18EL-362 (see program format numbers below under Registration)

Educational Track: Technical/Clinical
Topic: Transfusion Medicine (Hemovigilance)
Intended Audience: Hospitals, Hospital Blood Banks, Medical Directors, Nurses, Physicians, Residents/Fellow, Students (MD, MT, SBB), Transfusion Safety Officer
Teaching Level: Basic to Advanced

Director/ Moderator: Barbee Whitaker, PhD, Senior Director, Research, AABB, Bethesda, MD
Speakers: Yanyun Wu, MD, Chief Medical Officer, BloodWorks, Seattle, WA; Chester Andrzejewski, MD, Medical Director, System Transfusion Medicine, Baystate Medical Center, Springfield, MA; Jo Wiersum, MD, Transfusion and Transplantation Reactions in Patients (TRIP), Netherlands

Learning Objectives

After participating in this educational activity, participants should be able to:

  • Describe the proposed changes to the definition of TACO and the reasons these changes have been proposed.
  • Differentiate between when to categorize transfusion reactions as "Other" and as "Unknown."
  • Define the major elements of the FDA Postmarketing Safety Reporting Requirements for Human Drug and Biological Products and the new requirements for transfusion reaction reporting.

Program Description

This session will include a review of the proposed revision to the ISBT definition of Transfusion Associated Circulatory Overload (TACO), the justification for the changes and the potential impact. Hemovigilance reporting includes options to categorize reactions as "Other" and "Unknown." A guide to the appropriate and inappropriate use of these reaction types will be presented along with analysis of the use of these categories in US Hemovigilance. This session will include a discussion of the FDA Postmarketing Safety Reporting Requirements for Human Drug and Biological Products and the impact on hemovigilance reporting.


   Program #
Single Viewer: Live Register18EL-362-2032
Single Viewer: On-Demand Register18EL-362-4032
Group Viewing: Live Register18EL-362-6032
Group Viewing: On-Demand Register18EL-362-8032
Group Viewing: Live & On-Demand Register18EL-362-9932

Speaker Biographies

Dr. Jo Wiersum obtained her medical degree in Leiden in 1981 and went on to work in the UK and the Republic of Guinea (West Africa). Since 1996 she has worked as a donor physician for the Dutch blood supply organisation, Sanquin. In 2000 she completed specialty training in community medicine. Since 2002 when the Dutch national hemovigilance office TRIP started, she has been its national medical coordinator. TRIP stands for Transfusion and Transplantation Reactions in Patients because it also handles reports on tissue and cell vigilance. Jo has chaired of the International Society for Blood Transfusion haemovigilance working party since 2011. In 2013 she obtained a PhD in medicine on a thesis entitled Hemovigilance: is it making a difference to safety in the transfusion chain.

Dr. Yanyun Wu came to Bloodworks in 2013 from Yale University, where she was Associate Medical Director for Transfusion Service, Apheresis Service, and Cellular Therapy Laboratories at the Yale-New Haven Hospital, and Associate Professor in the School of Medicine. She is recognized globally for her knowledge of transfusion practices, apheresis therapies, physician collaboration and regulatory processes. As an adjunct faculty member of Yale University, she continues to participate in large NIH-sponsored research projects, and in particular promotes transfusion medicine education in China.  She holds multiple visiting faculty appointments in China, including chair professorship for Peking Union Medical College.